These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1133 related items for PubMed ID: 19089890

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [Abstract] [Full Text] [Related]

  • 5. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z.
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [Abstract] [Full Text] [Related]

  • 6. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG, Al-Buheissi S.
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z.
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL.
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [Abstract] [Full Text] [Related]

  • 15. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study.
    Chompootaweep S, Nunthapisud P, Trivijitsilp P, Sentrakul P, Dusitsin N.
    Clin Pharmacol Ther; 1998 Aug; 64(2):204-10. PubMed ID: 9728901
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J, Shaffu B, Anand C, Powell C.
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
    Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, Mistry A, Wright DM, Bolodeoku J, STAR study group.
    Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.